This study is the first administration of GSK2983559, a selective receptor interacting
protein 2 (RIP2) kinase inhibitor, to humans. This will be randomized, double-blinded
(sponsor open) and two part study (A and B). Part A of the study is single ascending dose
crossover design with two separate cohorts (1 and 2). In Part A, 9 single dose levels will be
explored. In Cohort 1, 10 healthy subjects will randomized to receive single oral doses of
either GSK2983559 or placebo in a ratio of 4:1 in 5 way cross-over design with 5 treatment
periods. In Cohort 2, 8 healthy subjects will be randomized to receive single oral doses of
either GSK2983559 or placebo in a ratio of 3:1 in 4 way cross-overs design with 4 treatment
periods. In Cohort 2 there will be an additional period (period 5-open label) for assessing
GSK2983559 under fed conditions. There will be 48 hours wash-out period between each dose
escalation period. Part B is repeat ascending dose sequential group design. It will contain 4
Cohorts of and dosing will be done sequential dosing. Subjects in Part B will receive once
daily (QD) dose or twice daily dose (will be decided based upon the pharmacokinetic, safety
and tolerability observed in Part A). There will 58 subjects involved in this study. Total
duration of Part A will be approximately for 11 Weeks and Part B will be approximately for 15
Weeks.